CA2841851A1 — Composition and method for treating hpv
Assigned to Universite Libre de Bruxelles ULB · Expires 2013-01-24 · 13y expired
What this patent protects
The present invention relates to lyophilized compositions comprising cidofovir, hydroxypropyl methylcellulose (HPMC) or hydroxyethylcellulose (HEC) and optionally a plasticizer. In particular, the present invention relates to such compositions which form a sheet-shaped porous sol…
USPTO Abstract
The present invention relates to lyophilized compositions comprising cidofovir, hydroxypropyl methylcellulose (HPMC) or hydroxyethylcellulose (HEC) and optionally a plasticizer. In particular, the present invention relates to such compositions which form a sheet-shaped porous solid matrix. The invention also relates to methods for producing such compositions. The invention further relates to such compositions for use in treating human papillomavirus (HPV) infections and HPV-associated malignancies, in particular HPV lesions and cervical cancer.
Drugs covered by this patent
- Zovirax (ACYCLOVIR) · Ligand Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.